These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25079038)

  • 1. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
    Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
    Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
    [No Abstract]   [Full Text] [Related]  

  • 2. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
    Naito K; Kobayashi M; Sahara N; Shigeno K; Nakamura S; Shinjo K; Tobita T; Takeshita A; Ohno R; Ohnishi K
    Int J Hematol; 2006 May; 83(4):318-23. PubMed ID: 16757431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
    Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
    Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
    Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
    Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral arsenic treatment of leukemia and the risk of porphyria.
    Au WY; Tam S; Fong BM; Kwong YL
    Leuk Res; 2009 Apr; 33(4):598-600. PubMed ID: 18829106
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
    Kajiguchi T; Yamamoto K; Sawa M; Emi N; Naoe T
    Leukemia; 2005 Apr; 19(4):674-6. PubMed ID: 15690072
    [No Abstract]   [Full Text] [Related]  

  • 9. Arsenic trioxide.
    Wilkinson K
    Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
    Zhou J; Meng R; Yang BF
    Chin Med Sci J; 2005 Jun; 20(2):137. PubMed ID: 16075757
    [No Abstract]   [Full Text] [Related]  

  • 11. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
    Yamakura M; Tsuda K; Ugai T; Sugihara H; Nisihida Y; Takeuchi M; Matsue K
    Acta Haematol; 2014; 131(2):76-7. PubMed ID: 24081111
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
    Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
    Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
    Firkin F; Roncolato F; Ho WK
    Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
    Au WY; Cheung GT; Yuen TW; Kumana CR; Kwong YL
    Arch Intern Med; 2005 May; 165(9):1067-8. PubMed ID: 15883249
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of Novoseven for arsenic trioxide-induced bleeding in PML.
    Alimoghaddam K; Ghavamzadeh A; Jahani M
    Am J Hematol; 2006 Sep; 81(9):720. PubMed ID: 16804937
    [No Abstract]   [Full Text] [Related]  

  • 16. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
    Shigeno K; Naito K; Sahara N; Kobayashi M; Nakamura S; Fujisawa S; Shinjo K; Takeshita A; Ohno R; Ohnishi K
    Int J Hematol; 2005 Oct; 82(3):224-9. PubMed ID: 16207595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 18. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
    Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
    Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
    Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
    Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.